Over $20 Million Carved Out From Statistical, Operations enters 2

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI: NCTN Makes “Amazing Trials” Possible

“It is important to note that the $151 million does not capture the many other functions that NCI provides in support of the NCTN and the entire clinical trials enterprise,” Garrett said. “A few of these key centralized functions include the Cancer Trials Support Unit (CTSU), a ‘one-stop shop’ for the groups to access all trials, a Central Institutional Review Board (CIRB) to eliminate the need for local IRB approvals, tumor banking for each group, and ancillary studies funded to support biomarker and quality of life research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login